Gilde Buy Out Partners acquires Oystershell

Gilde did not confirm whether it secured a majority or minority stake in Oystershell.

The GP is currently investing from Gilde Fund V, which closed on €1.1bn in 2016. The fund follows a similar strategy to its predecessors, investing in mid-market companies with a core focus on the Benelux and DACH regions. The vehicle deploys equity tickets of €30-120m in deals with enterprise values of between €100-250m.

Other portfolio companies for Fund V currently include Netherlands-based Royal Reesink and Germany-based companies  Amor Group and Losberger, all acquired in 2016.

As Oystershell's new shareholder, Gilde will support the company's growth plan, focused on further internationalisation and development into new areas of the OTC healthcare market.

Company
Formed in 2002 from a carve-out from a larger industrial group, Oystershell is an OTC healthcare products manufacturer. The company is especially known for its treatments against lice, insects and warts.

Headquartered in Ghent, Belgium, Oystershell sells its products in 30 countries, directly as well as in partnership with its clients, which are mostly active in the OTC healthcare market.

People
Gilde Buy Out Partners – Nicolas Linkens (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Buyouts
• Healthcare
• Belgium
• Benelux
• Gilde Buy Out Partners